The infrastructure of the United States pharmaceutical supply chain is governed by a highly scrutinized, dual-layered enforcement matrix. Because Schedule I and Schedule II controlled substances possess the highest potential for abuse, psychological dependence, and physical addiction within clinical medicine, their distribution pathways must be tightly insulated against diversion. At the baseline of this protective […]